Earnings Summary

Iteos Therapeutics Inc’s revenue fell -100% since last year same period to $0Mn in the Q3 2023. On a quarterly growth basis, Iteos Therapeutics Inc has generated NaN% jump in its revenue since last 3-months.

Iteos Therapeutics Inc’s net profit fell -3353.38% since last year same period to $-32.24Mn in the Q3 2023. On a quarterly growth basis, Iteos Therapeutics Inc has generated 6% jump in its net profits since last 3-months.

Iteos Therapeutics Inc’s net profit margin fell -Inf% since last year same period to -Inf% in the Q3 2023. On a quarterly growth basis, Iteos Therapeutics Inc has generated NaN% jump in its net profit margins since last 3-months.

Iteos Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.53 - a 55.83% jump from last quarter’s estimates.

Iteos Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.53.

Iteos Therapeutics Inc’s earning per share (EPS) fell -3100% since last year same period to -0.9 in the Q3 2023. This indicates that the Iteos Therapeutics Inc has generated -3100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Iteos Therapeutics Inc’s return on assets (ROA) stands at -0.08.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Iteos Therapeutics Inc’s return on equity (ROE) stands at -0.1.